ArticleNature communications2026
Transcript-aware rare genetic variant association analyses of cardiopulmonary traits in participants from the All of Us Research Program.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Gene-based rare variant analyses often lack statistical power and may overlook transcript-specific effects. Here, we present a transcript-aware aggregation framework. In simulation studies, the framework maintains appropriate false-positive rates and shows competitive power relative to standard single-transcript analyses, approaching the performance of the ideal case of knowing the most informative transcript in advance. We then apply the approach to 129 cardiopulmonary traits in over 240,000 whole-genome-sequenced All of Us participants. By leveraging transcript-specific annotations, we identify 11 novel associations and recover 47 reported associations, including potentially pleiotropic genes linked to plasma lipid traits (PPARG) and body habitus (TCF12). Notably, for TTN, a gene known for its transcript-specific effects in cardiomyopathy, our framework strengthens the association signal and pinpoints the N2B isoform, which shows a stronger association with cardiomyopathy than other transcripts. These findings highlight the value of a transcript-aware framework for improving rare variant association studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.